Pharma Equities Technical Data - Salix Pharma, AstraZeneca, Novartis, Impax Laboratories, and Novo Nordisk

Editor Note: For more information about this release, please scroll to bottom.

LONDON, November 11, 2014 /PRNewswire/ --

Investor-Edge has initiated coverage on the following equities: Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), AstraZeneca PLC (NYSE: AZN), Novartis AG (NYSE: NVS), Impax Laboratories Inc. (NASDAQ: IPXL), and Novo Nordisk A/S (NYSE: NVO). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 10, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,613.74, up 0.23% and the NASDAQ Composite closed at 4,651.62, up 0.41%. The S&P 500 finished the session 0.31% higher at 2,038.26. During the trading session, eight out of ten sectors finished on a higher note.  The S&P 500 Health Care Sector Index ended the day at 783.00, up 1.00%, with the index gaining 11.86% in the previous three months. Register for your complimentary reports on these five stocks at:  

http://investor-edge.com/register

Salix Pharmaceuticals Ltd.'s stock gained 2.62%, to close the day at $93.87. The stock recorded a trading volume of 4.53 million shares, much above its three months average volume of 2.32 million shares. The company's shares oscillated between $90.00 and $95.46 during the session. Over the last three trading sessions and over the past one month, Salix Pharmaceuticals Ltd.'s shares have plummeted 32.71% and 32.89%, respectively. Further, the stock has lost 26.83% in the past three months. The company's stock is trading below its 50-day and 200-day moving averages. Salix Pharmaceuticals Ltd. stock's 50-day moving average of $147.38 is above its 200-day moving average of $124.39. Additionally, the stock traded at a PE ratio of 102.35 and has a Relative Strength Index (RSI) of 16.96. Sign up and read the free notes on SLXP at:

www.Investor-Edge.com/SLXP-11Nov2014

On Monday, shares in AstraZeneca PLC recorded a trading volume of 1.19 million shares, lower than its three months average volume of 2.05 million shares. The stock ended the day at $73.21, which was 0.45% above its previous day's closing of $72.88, and registered an intraday range of $72.98 and $73.49. AstraZeneca PLC's shares have gained 7.02% in the last one month, 6.89% in the previous three months, and 23.31% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages of $71.69 and $70.79, respectively. Furthermore, shares of AstraZeneca PLC have an RSI of 60.04. The complimentary notes on AZN can be downloaded as in PDF format at:

www.Investor-Edge.com/AZN-11Nov2014

Novartis AG's stock advanced 0.95% to end Monday's session at $92.63. The stock recorded a trading volume of 0.82 million shares, below its three months average volume of 1.35 million shares. The company's shares fluctuated between $91.89 and $92.64 during the session. Novartis AG's shares have gained 15.24% since the beginning of 2014. Further, the stock has advanced 5.63% over the last one month and 8.53% in the previous three months. The company's stock is trading above its 50-day and 200-day moving averages. Novartis AG stock's 50-day moving average of $91.67 is above its 200-day moving average of $87.53. Additionally, the stock has an RSI of 54.45. Register for free on Investor-Edge and access the latest research on NVS at:

www.Investor-Edge.com/NVS-11Nov2014

On Monday, shares in Impax Laboratories Inc. fluctuated between $28.64 and $29.33 before ending the session 1.68% higher at $29.05. The stock reported a trading volume of 0.48 million shares, lower than its three months average volume of 0.60 million shares. Shares of the company traded at a PE ratio of 30.09. Impax Laboratories Inc.'s stock has gained 6.64% in the last one month, 23.72% in the previous three months, and 15.55% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages of $25.90 and $26.12, respectively. Moreover, shares of Impax Laboratories Inc. have an RSI of 62.30. The complete research on IPXL is available for free at:

www.Investor-Edge.com/IPXL-11Nov2014

Novo Nordisk A/S's stock finished Monday's session 0.89% lower at $43.30. A total of 2.23 million shares were traded, which was above its three months average volume of 1.35 million shares. The stock vacillated between $42.86 and $43.47 during the session. Over the previous three trading sessions and over the past three months, Novo Nordisk A/S's shares have fallen by 1.57% and 2.35%, respectively. However, from the beginning of 2014, the stock has gained an upside of 17.18%. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $45.87 is greater than its 200-day moving average of $44.88. Novo Nordisk A/S's stock has an RSI of 42.10. Free in depth research on NVO is available at:

www.Investor-Edge.com/NVO-11Nov2014

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Investor-Edge

Suggested Articles

That didn’t take long. Sanofi CEO Paul Hudson has only been at the reins for a couple months, but on Tuesday, he unveiled a major shakeup.  

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.